The global population is continually at risk for the emergence or reemergence of deadly viruses. The Ebola virus epidemic of 2014-2015 involved a known virus emerging in a new area (1, 2). The Severe Acute Respiratory Syndrome outbreak in 2002-2003 involved a novel virus from a family previously only known to cause relatively mild, cold-like symptoms in humans (3, 4) . Lujo virus, an arenavirus, emerged in southern Africa in 2008 (5) and killed 80% of those individuals infected. Sin Nombre virus, a novel hantavirus that causes cardiopulmonary distress, emerged in the Four Corners region of the United States in 1993 and rapidly sickened and killed otherwise young and healthy adults (6, 7). We can expect new pathogens to emerge over and over, but medical science will likely have no or few specific therapeutics on hand to treat those individuals infected, or prophylactics to protect contacts and frontline workers. What might medicine have to offer? And in what time frame could prophylactics and therapeutics be discovered and made available? In PNAS, Corti et al. (8) describe the discovery of a potent human neutralizing mAb against a novel beta coronavirus, Middle East Respiratory Syndrome (MERS) virus, 4 mo after conception of the project. They demonstrate prophylactic and postexposure efficacy in an animal model of MERS virus infection. Their study supports the notion that the generation of passive antibodies might be a general, rapid strategy to counter emerging pathogens, at least until effective small-molecule drugs and vaccines can be developed.
In April 2012, six hospital workers in Jordan were diagnosed with acute respiratory failure of unknown origin. Discovery of the causative agent, MERS virus, occurred in September 2012 (9). Over the next 2 y, additional cases were noted in the Middle East There have now been more than 1,300 documented cases and over 500 deaths from MERS worldwide, involving sporadic cases, small clusters, and large outbreaks (10, 11), most notably in Saudi Arabia following contact with camels, with the camels presumably infected by bats. Multiple genomic variants have been detected in domesticated camels in the Middle East, suggesting that the virus has been circulating for some time.
Antibodies have been delivered passively to protect against infection for millions of years in breast milk, ever since we became mammals. The first medical transfer of antibody, however, occurred 125 y ago by von Behring and Kitasato (12). Convalescent sera has been transfused into patients with hopes of improving survival in a number of infections (13-15), but such sera are limited in quantity, variable in potency, and offer safety concerns. Specific mAbs, however, allow scale-up, consistency, and safety (15).
Corti et al. (8) immortalized memory B cells from a MERS-convalescent donor several months after he recovered from infection, and tested supernates from single antibody-producing B cells for virus neutralization. The donor had a relatively weak neutralizing serum titer, and, indeed, only one of 4,600 B-cell supernates showed neutralizing activity. The mAb produced by the corresponding B-cell clone, dubbed LA60, was shown to neutralize a number of MERS virus strains potently at concentrations in the range of 0.1 to a few nanomolar. LA60 showed efficacy when given before or 1 d following exposure to virus in a mouse model of MERS infection. Doses of 1-15 mg/kg of body weight of mAb led to a reduction in viral titers of 2-4 logs on day 3, and to undetectable virus on day 5. Much smaller doses of 0.12 mg/kg were effective when delivered intranasally in controlling this respiratory pathogen. Replication and pathology are limited in this model, and the animal typically clears the virus by day 7, so efficacy in humans remains to be determined.
Through mutagenesis and biochemistry, the authors showed that LA60 binds to the receptor-binding domain (RBD) of the MERS spike protein, and thereby blocks interaction of the spike with the CD26 cellular receptor for the virus. Further, it cross-competes with some other known anti-MERS neutralizing antibodies, suggesting that these antibodies target overlapping epitopes. What are the implications of these studies? In the first instance, potent human mAbs can now be generated quickly by a variety of approaches following the discovery of a new pathogen (Fig. 1) . Scale-up of mAb production can also be achieved efficiently. The generation of animal models to test mAb efficacy in vivo can also be achieved expeditiously, given some molecular understanding of cell entry, as in the case of MERS virus. Having a human mAb in hand, a key time-saving step is likely to be in testing for use in humans. Safety profiles of antibodies are much better understood than other options, like novel small-molecule antivirals or vaccines. In general, mAbs have had a much higher success rate going through the regulatory pathway than small-molecule drugs and a shorter pathway to approval, and few safety problems have been reported (20) (21) (22) .
How can we organize to deliver mAbs most effectively as new viruses emerge? The likely requirement of more than one antibody to mitigate neutralization escape, the rarity of the most effective antibodies, and the number of unknowns in terms of the best correlates of protection for each pathogen together suggest cooperation of multiple laboratories in well-run consortia as a good way forward. 
